Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지

Inhibitory Action of the Natural Product AP1700 on the Withdrawal Syndrome of Nalbuphine

  • Kang, Jong-Seok (Graduate School of Sports Science, Korea National Sports University) ;
  • Lee, Hun-Kyu (Division of Drug Development, Aperio) ;
  • Kim, Dong-Hyun (Graduate School of Pharmacy, Chungbuk National University) ;
  • Yoo, Hwan-Soo (Graduate School of Pharmacy, Chungbuk National University) ;
  • Jang, So-Yong (Department of Neuroscience, School of Medicine, Ewha University) ;
  • Oh, Sei-Kwan (Department of Neuroscience, School of Medicine, Ewha University)
  • Published : 2005.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

The study was undertaken to determine the antagonism of the AP1700 on the development of nalbuphine-induced tolerance and physical dependence. AP1700 is an oriental drug preparationcomposed of 5 natural products and is known to have antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of antinarcotic action with an oral dose of 250 mg/kg in rats. AP1700 significantly inhibits the development of nalbuphine-induced physical dependence but does not the tolerance. Mitogen-activated protein kinase, which include extracellular signal-regulated kinase (ERK), p38 and c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK) play critical roles in cell growth and survival and drug abuse. The level of pCREB was elevated in the hippocampus by the chronic treatment with nalbuphine, however, the elevation of pCREB was not inhibited by the AP1700 co-treatment. Interestingly, the level of pERK was decreased in the co-treatment with nalbuphine and AP1700 on the cortex and striatum. However, the level of nNOS and NR1 was not modulated by the treatment with nalbuphine or AP1700 on the cortex, hippocampus and striatum in the rat brain. These results suggest that the AP1700 could be used to ameliorate the nalbuphine withdrawal symptoms.

Keywords

References

  1. Belcheva, M.W., Vogel, Z., Ignatova, E., Avidor-Reiss, T., Zippel, R., Levy, R, Young, E.C., Barg, I. and Coscia, C.J. (1998). Opioid modulation of extracellular signal-regulated protein kinase activity is Ras-dependent and involves $G{\beta}{\gamma}$ subunits. J. Neurochem. 70, 635-645 https://doi.org/10.1046/j.1471-4159.1998.70020635.x
  2. Berhow, M.T., Hiroi, N. and Nestler, E.J. (1996). Regulation of ERK, part of the neurotropin signal transduction cascade, in the rat meso limbic dopamine system by chronic exposure to morphine or cocaine. J. Neurosci. 16, 4707-4715
  3. Chen, J.C., Smith, E.R., Cahill, M., Cohen, R. and Fishman, J.R. (1992). The opioid receptor binding of pentazocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci. 52, 389-396
  4. Childers, S.R. (1991). Opioid receptor-coupled second messengers. Life Sci. 48, 1991-2003 https://doi.org/10.1016/0024-3205(91)90154-4
  5. Cuellar, B., Fernandez, A.P., Lizasoain, I., Moro, M.A., Lorenzo, P., Bentura, M.L., Rodrigo, J. and Leza, J.C. (2000) Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology (Berl.) 148, 66-73 https://doi.org/10.1007/s002130050026
  6. D' Amour, F.E. and Smith, D.L., (1942). A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72, 74-79
  7. Davis, R.J. (1993). The mitogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268, 14553-14556
  8. Ellman, G.L. (1959). Tissue sulfhydryl compounds on acute toxicity of morphinone. Arch. Biochem. Biophys. 82, 70-77 https://doi.org/10.1016/0003-9861(59)90090-6
  9. Fukunaga, K. and Miyamoto, E. (1998). Role of MAP kinase in neurons. Mol. Neurobiol. 16, 79-95 https://doi.org/10.1007/BF02740604
  10. Impey, S., Obrietan, K. and Storm, D.R. (1999). Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity. Neuron 23, 11-14 https://doi.org/10.1016/S0896-6273(00)80747-3
  11. Kim, D.S., Lim, H.K, Jang, S. and Oh, S. (2003). Changes of the level of G protein ${\alpha}$-subunit mRNA by tolerance to and withdrawal from butorphanol. Neurochem. Res. 28, 1771-1778 https://doi.org/10.1023/A:1026198820420
  12. Koob, G.F., Sanna, P.P. and Bloom, F.E. (1998). Neuroscience of addiction. Neuron 21, 467-476 https://doi.org/10.1016/S0896-6273(00)80557-7
  13. Koyuncuoglu, H., Dizdar, Y., Aricioglu, F. and Sayin, U. (1992). Efects of MK-801 on morphine physical dependence: attenuation and intensification. Pharmacol. Biochem. Behav. 43, 484-490
  14. Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S. (1982). Protective effect of sulfhydryl compounds on acute toxicity of morphinone. Life Sci. 30, 1121-1127 https://doi.org/10.1016/0024-3205(82)90533-1
  15. Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S. (1982). Effect of morphinone on opiate receptor binding and morphine-elicited analgesia. Life Sci. 31, 1451-1457 https://doi.org/10.1016/0024-3205(82)90006-6
  16. Nagamatsu, K., Kido, Y., Terao, T., Ishida, T. and Toki, S.(1983). Studies on the mechanism of covalent binding of morphine metabolites to proteins in mouse. Drug Meta. Dispos. 11, 190-194
  17. Nestler, E.J. (1996). Under siege: the brain on opiates. Neuron 16, 897-900 https://doi.org/10.1016/S0896-6273(00)80110-5
  18. Nestler, E.J., Hyman, S.E. and Malenka, R.C. (2001). Signalling to the nucleus. pp 115-137. in Molecular neuropharmacology, McGraw-Hill, New York
  19. Nestler, E.J. (1992). Molecular mechanisms of drug addiction. J. Neurosci. 12, 2439-2450
  20. Noda, Y., Yamada, K., Komori, Y., Sugihara, H., Furukawa, H., Nabeshima, T. (1996) Role of nitric oxide in the development of tolerance and sensitization to behavioral effects of phencyclidine in mice. Br. J. Pharmacol. 204, 339-340
  21. Oh, S., Kim, J.I., Chung, M.W. and Ho, I.K. (2000). Modulation of NMDA receptor subunit mRNA in butorphanol-tolerant and - withdrawing rats. Neurochem. Res. 25, 1603-1611 https://doi.org/10.1023/A:1026618603795
  22. Ozaki, S., Narita, M., Narita, M., Ozaki, M., Khotob, J. and Suzuki, T. (2004). Role of extracellular signal-regulated kinase in the ventral tegmental area in the suppression of the morphine-induced rewarding effect in mice with sciatic nerve ligation. J. Neurosci. 88, 1389-1397
  23. Penning, J.P., Samson, B., Baxter, A.D. (1988). Reversal of epidural morphine-induced respiratory depression and pruritus with nalbuphine. Can. J. Anaesth. 35, 599-604 https://doi.org/10.1007/BF03020347
  24. Rhim, H. and Miller, R.J. (1994). Opioid receptors modulate diverse types of calcium channels in the nucleus tractus solitarius of the rat. J. Neurosci. 14, 7608-7615
  25. Schmidt, W.K., Tam, S.W., Shotzberger, G.S., Smith, D.H. Jr, Clark, R. and Vernier, V.G. (1985). Nalbuphine. Drug Alcohol Depend. 14, 339-362 https://doi.org/10.1016/0376-8716(85)90066-3
  26. Tokuyama, S., Wakabayashi, H. and Ho, I.K. (1996) Direct evidence for a role of glutamate in the expression of opioid withdrawal syndrome. Eur. J. Pharmacol. 295, 123-129 https://doi.org/10.1016/0014-2999(95)00645-1
  27. Walker, E.A. and Young, A.M. (1993). Discriminative-stimulus effects of the low efficacy ${\mu}$ agonist nalbuphine. J. Pharmacol Exp. Ther. 267, 322-330
  28. Zhang, Z., Xin, S.M., Wu, G.X., Zhang, W.B., Ma, L. and Pei, G. (1999). Endogenous ${\\delta}$-opioid and $ORL_1$ receptors couple to phosphorylation and activation of p38 MAPK in NG 108-15 cells and this is regulated by protein kinase A and protein kinase C. J. Neurochem. 73, 1502-1509 https://doi.org/10.1046/j.1471-4159.1999.0731502.x